BC Extra | Oct 31, 2019
Company News

Dicerna’s latest deal lands $200M, Roche as partner in HBV

A year after completing a pair of deals in the span of a week, Dicerna has partnered a Phase I HBV asset with Roche in an RNAi deal that brings in $200 million up front....
BC Week In Review | Oct 12, 2018
Company News

Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Oct. 9 after announcing updates for two of its HBV programs. The move translated to a loss of over $170 million in the company's market...
BC Extra | Oct 9, 2018
Clinical News

Arbutus falls on HBV program updates

Arbutus Biopharma Corp. (NASDAQ:ABUS) lost $3.09 (34%) to $6 on Tuesday after announcing updates for two of its HBV programs. The move translated to a loss of over $170 million in the company's market cap....
BC Week In Review | Sep 14, 2018
Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) reported initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating hepatitis B surface antigen (HBsAg) levels in a broad population of patients with chronic HBV infection....
BC Extra | Sep 6, 2018
Clinical News

Arrowhead's third-generation RNAi shows initial efficacy against HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained $5.29 (38%) to $19.39 Thursday after reporting initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating HBV surface antigen (HBsAg) in a broad population of...
BC Week In Review | Dec 1, 2017
Clinical News

Arbutus' ARB-1467 leads to HBsAg responses in Phase IIa for HBV infection

Arbutus Biopharma Corp. (NASDAQ:ABUS) reported data from 11 evaluable hepatitis B e antigen (HBeAg)-negative patients with chronic HBV infection in cohort 4 of the Phase IIa ARB-1467-002 trial showing that 0.4 mg/kg IV ARB-1467 every...
BC Innovations | Oct 12, 2017
Targets & Mechanisms

Mining the negatives

By investigating why its discontinued siRNA candidate against hepatitis B caused only weak responses in certain patients, Arrowhead Pharmaceuticals Inc. has upended a dogma about the virus’ genetics that has been clouding drug design and...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
BioCentury | May 23, 2016
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/20 cls Arbutus Biopharma Corp. (NASDAQ:ABUS) Chardan Capital Madhu Kumar New Sell -6% $4.08 Kumar initiated coverage with a $3.25...
BC Week In Review | Oct 12, 2015
Clinical News

Arbutus Biopharma preclinical data

In a mouse model of HBV infection, 4 weekly doses of 0.3 mg/kg TKM-HBV reduced HBV covalently closed circular DNA levels by 42% vs. untreated control animals. This quarter, Arbutus expects data from a Phase...
Items per page:
1 - 10 of 16